<DOC>
	<DOCNO>NCT02371512</DOCNO>
	<brief_summary>Study assess mitral valve reconstruction advance insufficiency functional ischemic origin patient moderate-to-severe mitral regurgitation ( MR ) primarily functional pathology reduce leave ventricular function consider high surgical risk</brief_summary>
	<brief_title>A Multicenter , Randomized , Controlled Study Assess Mitral vAlve reconsTrucTion advancEd Insufficiency Functional iscHemic ORigiN</brief_title>
	<detailed_description>Secondary functional mitral regurgitation ( MR ) result geometrical distortion dysfunctional leave ventricle lead tether mitral valve leaflet papillary muscle displacement , annular dilatation and/or reduce closing force structurally normal mitral valve . It occur 30 % patient systolic heart failure . Despite optimal medical care associate increased mortality hospitalization rate leave elimination MR therapeutic option . Nevertheless , traditionally , reconstructive mitral valve surgery ( RMVS ) therapy choice set . As RMVS far investigate retrospective single center registry , show conflict result . class IIb recommendation , level evidence C , patient without indication coronary revascularization current guideline European Society Cardiology . In recent year percutaneous mitral valve repair MitraClip ( PMVR ) evolve important therapeutic option type patient widespread use particularly Europe , device CE-marked 2008 . PMVR compare mitral valve surgery ( repair replacement ) randomize , control EVEREST II trial patient primary MR , good candidate surgery , show less effective surgery context . However , randomize , control data available compare PMVR RMVS patient depress left ventricular function secondary MR , considerably higher perioperative risk EVEREST II population . Like RMVS class IIb , level evidence C , recommendation current guideline .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Clinically significant mitral regurgitation primarily functional pathology Left Ventricular Ejection Fraction ( LVEF ) ≥20 % ≤45 % determined echocardiography High surgical risk determine Heart Team consensus Documented New York Heart Association Class III Class IV heart failure , despite optimal standard care therapy Written inform consent accordance Good Clinical Practice ( GCP ) local legislation Echocardiographic evaluation available suitable analysis baseline Severe tricuspid regurgitation accord current guidelines5 Other severe valve disorder require intervention accord current guidelineso 6Minute Walk Test baseline &lt; 50 Coronary revascularization cardiac resynchronization ( CRT ) device implantation within 3 month procedure Patient amenable mitral valve surgery/ percutaneous mitral valve reconstruction judge Heart Team Key information patient ( e.g . NYHA , MR grade ) available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Mitral Valve Insufficiency</keyword>
</DOC>